MichaelGlenKauffmanMDPhD

PubMed

• 26 citations
  Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib.
  Wenwen Chien, Makoto Sudo, Ling-Wen Ding, Qiao-Yang Sun, Peer Wuensche
  Journal of Cancer. 2018-12-10
• 11 citations
  Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression.
  Amro Aboukameel, Irfana Muqbil, Erkan Baloglu, William Senapedis, Yosef Landesman
  Oncotarget. 2018-10-19
• 41 citations
  Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
  Trinayan Kashyap, Christian Argueta, Thaddeus J. Unger, Boris Klebanov, Sophia A. Debler
  Oncotarget. 2018-07-20

Abstracts/Posters

• Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018